RxDoctor Payments Data

Alejandro Chediak, MD

Sleep Medicine · South Miami, FLNPI 1669401774

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.5%), consulting fees and education — rather than concentrated in one kind of arrangement. Jazz Pharmaceuticals Inc. accounts for 63.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $2,407 and has fallen 52.7% since, to $1,138 in 2025.

$5,375in general payments, 2019–2025

Across 80 payments — averaging $67.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$3K
  • Harmony Biosciences LLC$841
  • Resmed Corp$407
  • Avadel CNS Pharmaceuticals, LLC$335
  • Axsome Therapeutics, Inc.$194
  • Fisher & Paykel Healthcare Inc$79
  • plus $94 from 2 others

What the payments were for

  • Consulting fees$2,00037%
  • Food & beverage$3,09057%
  • Education$2855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,375 in reported general payments places this provider in the 65th percentile of 77 sleep medicine providers in Florida.

See all sleep medicine providers in Florida

Medicare billing

Part B allowed, 2024
$66,387
Medicare patients
456
Services billed
755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant31$13,264
Doxepin Hcl100$10,772
QuviviqDaridorexant Hcl20$9,733
SymbicortBudesonide/Formoterol Fumarate13$3,135
Ramelteon13$1,682
Modafinil12$599
Zolpidem Tartrate59$502
Eszopiclone18$362
Clonazepam38$306
Gabapentin24$299
Pramipexole DihydrochloridePramipexole Di-Hcl17$280
Fluticasone Propionate16$270
Ropinirole Hcl15$248
Zaleplon11$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Idorsia Pharmaceuticals US IncQuviviq$16$9,73320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 77 sleep medicine providers in Florida.

Other sleep medicine in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →